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Both genetic approaches and small-molecule inhibitors can be used to perturb protein 
function. Banaszynski et al. (2006) now describe a strategy to regulate the stability of a 
target protein, in which specificity is provided by a genetically encoded tag and temporal 
control is imparted by a small molecule.Much of our understanding of biology 
at the molecular level has emerged 
because of the development of strat-
egies to perturb the function of pro-
teins, including genetic approaches, 
RNA interference (RNAi), and the 
use of small molecules. With genet-
ics, the timescale of the perturbation 
depends on the development of the 
organism (or with RNAi on the half-
life of the protein). In contrast, inhibi-
tion by small molecules is rapid (with 
timescales of seconds to minutes) 
and often reversible, as binding is 
often not covalent. The use of small-
molecule inhibitors has a rich history. 
Classic examples include the use of 
colchicine and Brefeldin A to examine 
cell division and membrane traffick-
ing, respectively (reviewed in Inoue 
and Sato, 1967; Jackson, 2000). 
However, the strength of genetics is 
that it can be applied to any protein 
with superb specificity because any 
gene can be targeted for mutation 
or deletion without directly affect-
ing any other gene. In contrast, the 
use of small molecules is limited to 
those proteins for which inhibitors 
have been identified, and discovery 
of new inhibitors is challenging. Also, 
it is difficult to demonstrate that a 
small molecule is specific for a single 
target, and specificity often depends 
on the concentration of the inhibitor 
that is used.
An ideal strategy would combine 
the specificity of genetics with the 
temporal control and reversibility of 
small molecules. Progress toward 
this goal has been made by design-ing mutations or genetically encoded 
tags that make the target protein, 
but not endogenous unmodified 
proteins, susceptible to a small mol-
ecule (reviewed in Shogren-Knaak 
et al., 2001). In this issue of Cell, 
Banaszynski et al. (2006) add to the 
arsenal of approaches that follow 
this general design. They describe a 
strategy in which a small molecule is 
used to control the degradation of a 
genetically tagged target protein.
Several strategies to control pro-
tein degradation with small mol-
ecules have been described previ-
ously (reviewed in Banaszynski and 
Wandless, 2006). One attractive 
approach has been to exploit the 
FKBP-rapamycin-FRB complex (see 
Table 1 for nomenclature). Rapamy-
cin is a small molecule that binds 
to the immunophilin FKBP12; the 
rapamycin-FKBP12 complex then 
binds to the FRB domain of FRAP/
mTOR. In one approach implemented Cell 126, Sepin yeast, FKBP was fused to a subu-
nit of the proteasome and FRB was 
used to tag a target protein (Janse et 
al., 2004). Upon addition of rapamy-
cin, the target protein was success-
fully localized to the proteasome and 
degraded. In a second approach, a 
fusion protein comprising FKBP and 
green fluorescent protein (GFP) was 
targeted for proteasomal degrada-
tion by treatment with a bifunctional 
small molecule containing both an 
FKBP ligand and a ligand for an E3 
ubiquitin ligase (Schneekloth et al., 
2004). In a third approach, which 
served as the starting point for the 
current study, a target protein, the 
kinase GSK-3β, was fused to the 
FRB domain (Stankunas et al., 2003). 
The idea was to develop an inducible 
dimerization system based on the 
binding of the rapamycin-FKBP12 
complex to the FRB domain. To 
avoid any effects of rapamycin on 
endogenous proteins containing FRB Table 1. Rapamycin-FKBP-FRB Nomenclature
Rapamycin Natural product, small molecule ligand for FKBP12; immunosup-
pressant drug
FKBP12 12 kDa FK506 binding protein. Rapamycin-FKBP12 complex binds 
to the FRB domain of FRAP.
FRAP FKBP12-rapamycin-associated protein, also known as mTOR.
FRB FKBP-rapamycin binding domain of FRAP/mTOR.
FRB* FRB with three point mutations, designed to bind rapamycin analogs 
such as MaRAP.
MaRAP C20-methallylrapamycin, synthetic rapamycin derivative that binds 
FRB* but not wt-FRB.
Shld1 Shield-1, FKBP ligand that binds FKBP with F36V mutation with 
1000 selectivity over wt-FKBP.tember 8, 2006 ©2006 Elsevier Inc. 827
domains, a mutated FRB domain 
(FRB*) was used with a rapamycin 
analog (MaRAP) that binds to FRB* 
but not wild-type FRB. The surprising 
finding was that GSK-3β-FRB* was 
degraded when expressed in mouse 
fibroblasts, whereas GSK-3β-FRB or 
unmodified GSK-3β remained stable. 
Furthermore, treatment with rapamy-
cin or MaRAP stabilized the GSK-
3β-FRB* fusion protein. A knockin 
mouse was constructed with GSK-
3β-FRB* to demonstrate that levels 
of GSK-3β could be controlled in vivo 
using a small molecule.
Banaszynski and colleagues set 
out to address some shortcomings in 
the strategy that uses MaRAP-FRB* 
for the inducible stabilization of a tar-
get protein. First, as MaRAP binds 
to FKBP12 in order to bind FRB, 
two protein domains are required 
for stabilization. Second, MaRAP is 
not ideal as a ligand, as it is expen-
sive and has poor pharmacokinetic 
properties that are likely related to 
its short half-life in serum (Stanku-
nas et al., 2003). The goal of the cur-
Figure 1. Timescales of Biological Proc-
esses and Experimental Perturbations
The use of perturbations that act on a relevant 
timescale facilitates the design of experiments 
to probe complex biological systems.828 Cell 126, September 8, 2006 ©2006 rent study was to identify an alterna-
tive ligand-dependent destabilizing 
domain. FKBP12 was selected as a 
candidate, in part because a wide 
variety of synthetic ligands are avail-
able. In particular, a ligand had been 
developed that binds to a mutated 
FKBP12 (bearing a F36V mutation) 
with 1000-fold selectivity over wild-
type FKBP12 (Clackson et al., 1998). 
A modified version of this ligand with 
improved pharmacokinetic proper-
ties, called Shield-1 (Shld1), was 
used in the current study.
To identify mutations in FKBP that 
might make it stable in the pres-
ence but not the absence of ligand, 
an FKBP library was generated by 
error-prone PCR and used to tag 
yellow fluorescent protein (YFP). 
This library was expressed in mouse 
fibroblast cells, and the cells were 
sorted by flow cytometry. After sev-
eral rounds of sorting, a population 
of cells was isolated that exhibited 
YFP fluorescence in the presence 
but not the absence of ligand, sug-
gesting that the ligand prevented 
destabilization of the tagged YFP. 
For the mutation in FKBP that was 
the most destabilizing (L106P), 
YFP was degraded almost com-
pletely within 4 hr after removal of 
the ligand. To demonstrate that 
this may be a general approach to 
affect protein stability, several dif-
ferent proteins were tagged with 
the destabilizing domain. Examples 
include several classes of proteins, 
such as kinases, small GTPases, 
and a transmembrane glycopro-
tein. Ligand-dependent stabilization 
was observed in all cases. Consti-
tutively active mutants of several 
small GTPases (RhoA, Cdc42, and 
Arl7) tagged with the destabiliz-
ing domain were used to show that 
cellular phenoyptes could be con-
trolled by adding or removing the 
ligand. In each case the expected 
morphological change associated 
with expression of the active mutant 
was observed in the presence of lig-
and. The phenotypes were reversed 
after removal of ligand.
There are some limitations to 
this approach. Although levels of a 
tagged protein may be controlled, the Elsevier Inc.endogenous protein is unaffected. 
In genetic systems, a knockin strat-
egy would circumvent this problem, 
as was demonstrated for the desta-
bilizing FRB* domain (Stankunas et 
al., 2003). Alternatively, dominant-
negative or constitutively active 
constructs can be used to introduce 
perturbations that do not depend 
on removing the endogenous pro-
tein. Ironically, this strategy is remi-
niscent of those used before the 
advent of RNAi when such methods 
were often the only ones available 
for systems not amenable to genetic 
approaches, such as cultured cell 
lines. Of course, the advantage of 
expressing these constructs with 
the destabilizing domain is that the 
perturbation can be introduced with 
a higher degree of temporal con-
trol and is reversible. The temporal 
control depends either on protein 
synthesis or on degradation of the 
tagged protein by the proteasome, 
depending on whether the ligand is 
added or removed. As the efficiency 
of both processes likely varies 
across the cell cycle, the effective-
ness of the technique may depend 
on cell-cycle state.
The approach described by 
Banaszynski and colleagues offers 
a promising compromise between 
the use of genetics and small mole-
cules. It should allow perturbations 
of protein function on timescales 
considerably shorter than either 
genetics or RNAi, though not as 
rapid as direct small-molecule inhi-
bition (Figure 1). The FKBP tag can 
in principle be added to any protein, 
which makes the technique more 
generally applicable than small-
molecule inhibition. However, not all 
proteins may be easily tagged and 
the endogenous protein must be 
accounted for. The combination of 
temporal control on a timescale of 
hours with the specificity of a sim-
ple genetically encoded tag should 
provide a valuable addition to the 
continually expanding toolbox for 
chemical biology. A future goal 
may be to employ a similar strategy 
with a tag that can be removed in a 
chemically controlled way, leaving 
the protein in a wild-type state.
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domain is transduced to modulate the 
enzymatic activity of the kinase.
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Hulko et al. analyzed the genome of 
Archaeoglobus fulgidus, a hyperther-
mophilic archaeon, and found a puta-
tive transmembrane receptor, Af1503, 
whose cytoplasmic domain contains 
only a HAMP domain. This 56 residue 
HAMP domain was soluble and well 
folded as a dimer when expressed in 
Escherichia coli. Subsequent analysis 
of its NMR structure revealed that this 
HAMP domain comprises a homodi-
meric, four-helical, parallel coiled-coil 
structure with unusual interhelical 
packing (Figure 1).
A 13 residue loop connects two 
helices (α1 and α2) of each monomer 
in a right-handed orientation. These 
two helices are of the same length 
and are offset by one helical turn. 
The structure of the connector shows 
several interesting features. It has 
a large extended confirmation that 
spans the 26 Å distance between the 
C-terminal and N-terminal ends of the 
α1 and α2 helices, respectively. The 
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